(2023). External validation of the QLifetime cardiovascular risk prediction tool: population cohort study. Bmc Cardiovasc Disord, 23, 194. http://doi.org/10.1186/s12872-023-03209-8.
(2022). Effect of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population. Bmj Med, 1, e000316. http://doi.org/10.1136/bmjmed-2022-000316.
(2023). Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. Lancet Healthy Longev, 4, e43-e53. http://doi.org/10.1016/s2666-7568(22)00290-2.
(2022). Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study. Bmc Med, 20, 152. http://doi.org/10.1186/s12916-022-02349-6.
(2016). Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. Br J Clin Pharmacol. http://doi.org/10.1111/bcp.13006.
(2016). Associations between exemption and survival outcomes in the UK\textquoterights primary care pay-for-performance programme: a retrospective cohort study. BMJ Qual Saf. http://doi.org/10.1136/bmjqs-2015-004602.
(2017). Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. http://doi.org/10.1186/s12916-017-0781-0.
(2021). Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. Lancet Healthy Longev. http://doi.org/10.1016/s2666-7568(21)00088-x.